GlassScriptPhysician profile
Alan H Slater
NPI 1770586364
$6,180.52
in general payments reported to CMS, 2019-2025
31 companies · $631 in 2025
The $631 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,080 · 2020: $798 · 2021: $504 · 2022: $440 · 2023: $1,156 · 2024: $571 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,358.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,576.32 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Abbott Laboratories | $1,150.48 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Jot Dx, Cardiomems |
| Medtronic, INC. | $683.06 | 2021-2025 | Micra, Cobalt Dr Mri Surescan, Linq II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.28 | 2019-2021 | |
| Amgen INC. | $303.55 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $296.70 | 2019-2020 | |
| Medtronic Vascular, INC. | $210.89 | 2019 | |
| Amarin Pharma, INC. | $150.18 | 2019-2020 | |
| Genzyme Corporation | $149.03 | 2019-2022 | |
| Abiomed | $143.39 | 2023 | Impella |
| Irhythm Technologies, INC. | $137.13 | 2020 | |
| Janssen Scientific Affairs, LLC | $136.71 | 2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $88.70 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $88.33 | 2019-2021 | |
| Atricure, INC. | $77.59 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $71.47 | 2019-2020 | |
| Pfizer INC. | $71.33 | 2019-2020 | |
| Gilead Sciences, INC. | $57.43 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $54.99 | 2019-2020 | |
| Daiichi Sankyo INC. | $53.93 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $52.60 | 2019-2020 | |
| Edwards Lifesciences Corporation | $49.58 | 2019 | |
| Akcea Therapeutics, INC. | $45.36 | 2019 | |
| Biotronik INC. | $40.75 | 2019-2020 | |
| Heartflow, INC. | $36.57 | 2025 | |
| Lantheus Medical Imaging, INC. | $34.14 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $26.45 | 2019 | |
| Esperion Therapeutics, INC. | $23.83 | 2020 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Portola Pharmaceuticals, LLC | $20.36 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Slater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.